Risk of rhabdomyolysis from 5-α reductase inhibitors.

Blayne WelkEric McArthurMichael OrdonJade DirkStephanie DixonAmit X Garg

Published in: Pharmacoepidemiology and drug safety (2018)

5-α reductase inhibitors do not appear to be associated with the development of rhabdomyolysis; however, they may be associated with an increased risk of myopathy and myositis.

Keyphrases

acute kidney injury
late onset
interstitial lung disease
muscular dystrophy
duchenne muscular dystrophy